Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | KIT | P10721 | 6/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.64 |
| ▸ | KDR | P35968 | 5/20 | 0.64 |
| ▸ | LCK | P06239 | 3/20 | 0.64 |
| ▸ | SRC | P12931 | 2/20 | 0.64 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.63 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.63 |
| ▸ | CSF1R | P07333 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30523366 | 1.00 | MAPT (0.68) | MAPTHTTMEN1RAB9AKMT2A | |
| SCHEMBL2497760 | 0.90 | MEN1 (0.68) | MAPTHTTMEN1RAB9AKMT2A | |
| SCHEMBL12858514 | 0.88 | MAPT (0.74) | MAPTHTTMEN1RAB9AKMT2A | |
| SCHEMBL2970952 | 0.86 | MAPT (0.70) | MAPTHTTMEN1RAB9AKMT2A | |
| SCHEMBL1264375 | 0.86 | MAPT (0.74) | MAPTHTTMEN1RAB9AKMT2A | |
| SCHEMBL20467572 | 0.86 | MAPT (0.70) | MAPTHTTMEN1RAB9AKMT2A | |
| SCHEMBL2313285 | 0.85 | MAPT (0.68) | MAPTHTTMEN1RAB9AKMT2A | |
| SCHEMBL16121292 | 0.85 | MAPT (0.68) | MAPTHTTMEN1RAB9AKMT2A | |
| SCHEMBL2975743 | 0.85 | MAPT (0.68) | MAPTHTTMEN1RAB9AKMT2A | |
| SCHEMBL29561542 | 0.85 | MAPT (0.68) | MAPTHTTMEN1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116761801-A | Heterocyclic compounds having protein kinase inhibitory activity, pharmaceutical compositions containing the same, and methods of preparing and using the same | 四川科伦博泰生物医药股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| WO-2022188792-A1 | HETEROCYCLIC COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2022-09-15 | — | — | WO | disclosed |
| US-20220194943-A1 | RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2022-06-23 | — | — | US | disclosed |
| CN-108467369-B | Biaryl amide compounds as kinase inhibitors | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2019-04-02 | — | — | US | disclosed |
| EP-3299367-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN INC (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN INC (US) | 2018-02-08 | — | — | US | disclosed |
| EP-2043638-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| WO-2008008821-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008821-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| CN-101039914-A | Trifluoromethyl substituted benzamide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2007-09-19 | — | — | CN | disclosed |
| EP-1778640-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006015859-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-02-16 | — | — | WO | disclosed |
| US-20060035897-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | MAP3K1, MAP3K20, MAP3K2 | MAPT 2516/4885HTT 3204/4885MEN1 1933/4885 |
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K2 | MAPT 2008/4885HTT 3866/4885MEN1 3854/4885 |
| US-20060035897-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | ABL1, ERBB2, EPHB2 | MAPT 3074/4885HTT 4489/4885MEN1 2511/4885 |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | MAPT 1965/4885HTT 3841/4885MEN1 2240/4885 |
| US-20220194943-A1 | RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER | EPHA1, EPHB2, EPHB1 | MAPT 1468/4885HTT 2881/4885MEN1 2634/4885 |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | MAPT 1965/4885HTT 3841/4885MEN1 2240/4885 |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | MAPT 1965/4885HTT 3841/4885MEN1 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.